Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Met
Go back to Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Met| (NASDAQ: RVMD) | Delayed: 206.96 -3.06 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $210.02 | 52 Week High | $ | |||
| Open | $208.07 | 52 Week Low | $ | |||
| Day High | $213.00 | P/E | N/A | |||
| Day Low | $206.47 | EPS | $ | |||
| Volume | 1,235,955 | |||||
